Basic Information
| ID | DRAMP20884 |
|---|
| Sequence | KRFKKFFRKLKKSVKKRKKEFKKKPRVIGVSIPF |
|---|
| Length | 34 |
|---|
| Name | Cath-B |
|---|
| Source | Synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
|---|
| Pathogen | [Ref.29392557] Gram-positive bacteria: MRSA PS-2 (MIC=256 μg/ml);##Gram-negative bacteria, MRSA PS-7 (MIC=32 μg/ml), MRSA PS-18 (MIC=128 μg/ml), MRSA PS-45 (MIC=64 μg/ml), MRSA PS-46 (MIC=128 μg/ml), MRSA PS-50 (MIC=128 μg/ml), MRSA PS-59 (MIC=32 μg/ml), MRSA PS-84 (MIC=128 μg/ml), MRSA PS-131 (MIC=64 μg/ml), MRSA PS-139 (MIC=64 μg/ml), MRSA PS-162 (MIC=256 μg/ml), MRSA PS-165 (MIC=128 μg/ml), Staphylococcus aureus ATCC 25923 (MIC=32 μg/ml), Staphylococcus aureus ATCC 33591 (MIC=256 μg/ml);##Gram-negative bacteria: Escherichia coli ATCC 25922 (MIC=2 μg/ml), Escherichia coli ATCC 51446 (MIC=8 μg/ml), Klebsiella pneumoniae ATCC 700603 (MIC=32 μg/ml), Klebsiella pneumoniae ATCC 13883 (MIC=8 μg/ml) |
|---|
| Hemolytic Activity | [Ref.29392557] 0% haemolysis at 1.0 μg/ml, 0% haemolysis at 2.0 μg/ml, 0% haemolysis at 4.0 μg/ml, 0% haemolysis at 8.0 μg/ml, 3% haemolysis at 16.0 μg/ml, 3% haemolysis at 31.2 μg/ml, 3% haemolysis at 62.5 μg/ml, 3% haemolysis at 125.0 μg/ml, 3% haemolysis at 250.0 μg/ml, 4% haemolysis at 500.0 μg/ml, 5% haemolysis at 1000.0 μg/ml against human red blood cells |
|---|
| Cytotoxicity | [Ref.29392557] The cell viability of HUVEC is 118%, 100% and 75% at peptide concentrations of 35.5 μg/ml, 71 μg/ml and 113 μg/ml.## The cell viability of H9c2 is 123%, 97%, and 88% at peptide concentrations of 35.5, 71, and 113 μg/ml. |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Free |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 29392557 |
|---|
